AAAF Sponsoring Clinical Trial Investigation into treatments for Alopecia Areata

Trial Details: 

The Cost to Government and Disutility of Alopecia Areata and an Investigator-Initiated, Placebo-controlled, Clinical Trial Investigating the Efficacy of Two Treatments for Alopecia Areata

Alopecia areata is an autoimmune disease of the hair follicle that causes non-scarring hair loss. The exact cause is unknown however we know that T-cells mediate the disease.

Cyclosporin is an immunosuppressive agent that works by inhibiting T cell activation. This medication is currently used for a number of other dermatological diseases, including atopic dermatitis, psoriasis and urticaria. It has shown very promising results in patients with alopecia areata.

This study aims to quantify the effectiveness of cyclosporin for alopecia areata. Participants will be allocated to receive either cyclosporine or placebo for 12 weeks. Participants who successfully complete Stage 1 but do not respond to Cyclosporin will be eligible to roll-over to Stage 2, investigating the effectiveness of Tofacitinib. There are 11 visits to the clinic over the course of the 2 stages. All study visits and medications are free of cost to participants.

If you are aged 18 -65 years, reside in Victoria and have moderate to severe alopecia areata you may be eligible for this trial.

To assess your eligibility, please complete the questionnaire in the link above. Your details will be forwarded to the Trials team and they will contact you shortly. Alternatively, please contact the trials unit at Sinclair Dermatology at